{"id":"https://openalex.org/W2015509183","doi":"https://doi.org/10.1089/cbr.2005.20.557","title":"\u03b1-Particle Radioimmunotherapy of Disseminated Peritoneal Disease Using a 212 Pb-Labeled Radioimmunoconjugate Targeting HER2","display_name":"\u03b1-Particle Radioimmunotherapy of Disseminated Peritoneal Disease Using a 212 Pb-Labeled Radioimmunoconjugate Targeting HER2","publication_year":2005,"publication_date":"2005-10-01","ids":{"openalex":"https://openalex.org/W2015509183","doi":"https://doi.org/10.1089/cbr.2005.20.557","mag":"2015509183","pmid":"https://pubmed.ncbi.nlm.nih.gov/16248771"},"language":"en","primary_location":{"id":"doi:10.1089/cbr.2005.20.557","doi":"https://doi.org/10.1089/cbr.2005.20.557","is_oa":false,"landing_page_url":"https://doi.org/10.1089/cbr.2005.20.557","pdf_url":null,"source":{"id":"https://openalex.org/S87235987","display_name":"Cancer Biotherapy and Radiopharmaceuticals","issn_l":"1084-9785","issn":["1084-9785","1557-8852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Biotherapy and Radiopharmaceuticals","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066817014","display_name":"Diane E. Milenic","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diane E. Milenic","raw_affiliation_strings":["Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD","Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC-1088, Building 10, Bethesda, MD 20892, USA. dm71q@nih.gov"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"raw_affiliation_string":"Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC-1088, Building 10, Bethesda, MD 20892, USA. dm71q@nih.gov","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009112138","display_name":"Kayhan Garmestani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kayhan Garmestani","raw_affiliation_strings":["Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011509071","display_name":"Erik D. Brady","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erik D. Brady","raw_affiliation_strings":["Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039237147","display_name":"Paul S. Albert","orcid":"https://orcid.org/0000-0003-1658-1068","observed_orcids":["https://orcid.org/0000-0003-1658-1068"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul S. Albert","raw_affiliation_strings":["Biometric Research Branch, National Cancer Institute, Bethesda, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biometric Research Branch, National Cancer Institute, Bethesda, MD","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005399548","display_name":"Dangshe Ma","orcid":"https://orcid.org/0000-0002-5919-6402","observed_orcids":["https://orcid.org/0000-0002-5919-6402"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dangshe Ma","raw_affiliation_strings":["Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109516978","display_name":"Alia Abdulla","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alia Abdulla","raw_affiliation_strings":["Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5002401816","display_name":"Martin W. Brechbiel","orcid":"https://orcid.org/0000-0002-4012-1400","observed_orcids":["https://orcid.org/0000-0002-4012-1400"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin W. Brechbiel","raw_affiliation_strings":["Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":4.5845,"has_fulltext":false,"cited_by_count":99,"citation_normalized_percentile":{"value":0.94264882,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"20","issue":"5","first_page":"557","last_page":"568"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13561","display_name":"Chemical Reactions and Isotopes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3003","display_name":"Pharmaceutical Science"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alpha-particle-radioimmunotherapy","display_name":"alpha particle radioimmunotherapy","score":0.925000011920929},{"id":"https://openalex.org/keywords/lead-212","display_name":"lead-212","score":0.8209999799728394},{"id":"https://openalex.org/keywords/bismuth-213","display_name":"bismuth-213","score":0.8429999947547913},{"id":"https://openalex.org/keywords/bismuth-212","display_name":"bismuth-212","score":0.9750000238418579},{"id":"https://openalex.org/keywords/her2","display_name":"HER2","score":0.7360000014305115},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.8920000195503235},{"id":"https://openalex.org/keywords/peritoneal-metastases","display_name":"peritoneal carcinomatosis","score":0.7829999923706055},{"id":"https://openalex.org/keywords/therapeutic-index","display_name":"therapeutic index","score":0.5989999771118164},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8840000033378601},{"id":"https://openalex.org/keywords/repeated-dosing","display_name":"repeated dosing","score":0.6340000033378601}],"concepts":[{"id":"https://openalex.org/C2776146153","wikidata":"https://www.wikidata.org/wiki/Q7281276","display_name":"Radioimmunotherapy","level":4,"score":0.9311900734901428},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5928707718849182},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5559461712837219},{"id":"https://openalex.org/C2989005","wikidata":"https://www.wikidata.org/wiki/Q214963","display_name":"Nuclear medicine","level":1,"score":0.4888257384300232},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.20033439993858337},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.14230260252952576},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.12282174825668335},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.10426539182662964},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000512","descriptor_name":"Alpha Particles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D005434","descriptor_name":"Flow Cytometry","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007856","descriptor_name":"Lead Radioisotopes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009368","descriptor_name":"Neoplasm Transplantation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010532","descriptor_name":"Peritoneal Diseases","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D011863","descriptor_name":"Radioimmunoassay","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016499","descriptor_name":"Radioimmunotherapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D018734","descriptor_name":"Genes, erbB-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018796","descriptor_name":"Immunoconjugates","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1089/cbr.2005.20.557","doi":"https://doi.org/10.1089/cbr.2005.20.557","is_oa":false,"landing_page_url":"https://doi.org/10.1089/cbr.2005.20.557","pdf_url":null,"source":{"id":"https://openalex.org/S87235987","display_name":"Cancer Biotherapy and Radiopharmaceuticals","issn_l":"1084-9785","issn":["1084-9785","1557-8852"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Biotherapy and Radiopharmaceuticals","raw_type":"journal-article"},{"id":"pmid:16248771","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16248771","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer biotherapy & radiopharmaceuticals","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":37,"referenced_works":["https://openalex.org/W1572912927","https://openalex.org/W1841075178","https://openalex.org/W1862647508","https://openalex.org/W1869307723","https://openalex.org/W1941252725","https://openalex.org/W1961675910","https://openalex.org/W1968258219","https://openalex.org/W1970536180","https://openalex.org/W1974280529","https://openalex.org/W1980181948","https://openalex.org/W1993546257","https://openalex.org/W2015488412","https://openalex.org/W2028534390","https://openalex.org/W2036301633","https://openalex.org/W2043303586","https://openalex.org/W2043882164","https://openalex.org/W2048195498","https://openalex.org/W2048254406","https://openalex.org/W2050430487","https://openalex.org/W2066610908","https://openalex.org/W2066983733","https://openalex.org/W2070459956","https://openalex.org/W2082255225","https://openalex.org/W2089120635","https://openalex.org/W2096057211","https://openalex.org/W2096935769","https://openalex.org/W2098689260","https://openalex.org/W2127901889","https://openalex.org/W2131851186","https://openalex.org/W2163040193","https://openalex.org/W2164532418","https://openalex.org/W2165725317","https://openalex.org/W2169599162","https://openalex.org/W2173883894","https://openalex.org/W2406806003","https://openalex.org/W2567103223","https://openalex.org/W2952428408"],"related_works":["https://openalex.org/W2111043177","https://openalex.org/W2621153471","https://openalex.org/W7097601049","https://openalex.org/W1946144416","https://openalex.org/W2031259290","https://openalex.org/W2039862949","https://openalex.org/W2747680450","https://openalex.org/W2122878067","https://openalex.org/W1982272727","https://openalex.org/W7100765416"],"abstract_inverted_index":{"These":[0],"studies":[1,27],"demonstrate":[2],"the":[3,9,29,32,100,196,216],"feasibility":[4],"of":[5,11,23,31,40,82,109,126,152,163,180,192],"targeted":[6],"therapy":[7],"for":[8,58,104],"treatment":[10],"disseminated":[12],"peritoneal":[13],"disease":[14],"using":[15],"(212)Pb-labeled":[16],"Herceptin":[17],"as":[18,99,143],"an":[19],"in":[20,45,131,156,206,215],"vivo":[21],"generator":[22],"(212)Bi.":[24],"In":[25],"vitro":[26],"compare":[28],"potential":[30],"bismuth":[33,52],"radioisotopes,":[34],"(213)Bi":[35],"and":[36,94,198],"(212)Bi,":[37],"to":[38,118,145,172,177],"that":[39],"(212)Pb.":[41],"Overall,":[42],"(212)Pb":[43],"results":[44],"a":[46,77,132,193,212],"higher":[47],"therapeutic":[48],"index":[49],"than":[50],"either":[51],"radioisotope,":[53],"requiring":[54],"lower":[55],"radioactivity":[56],"(microCi)":[57],"effective":[59,101],"cytotoxic":[60],"response.":[61],"A":[62,88],"pilot":[63],"radioimmunotherapy":[64],"(RIT)":[65],"experiment":[66],"treating":[67],"mice":[68,111,164],"bearing":[69,165],"5":[70],"d":[71,167],"LS-174T":[72,168],"intraperitoneally":[73],"(i.p.)":[74],"xenografts":[75,170],"determined":[76],"maximum":[78],"tolerated":[79],"dose":[80,90,103],"(MTD)":[81],"20-40":[83],"microCi":[84,96,114],"with":[85,175,195,211],"i.p.":[86,169],"administration.":[87],"specific":[89],"response":[91],"was":[92,97,128,154,189,209],"observed":[93],"10":[95,113],"selected":[98],"operating":[102],"future":[105],"experiments.":[106],"Median":[107],"survival":[108,162,208],"tumor-bearing":[110],"receiving":[112],"increased":[115,171],"from":[116],"19":[117],"56":[119],"days":[120],"(p":[121,147,201],"=":[122,148,202],"0.008).":[123],"The":[124,160],"efficacy":[125],"(212)Pb-Herceptin":[127,153,181],"also":[129],"assessed":[130],"human":[133],"pancreatic":[134],"carcinoma":[135],"xenograft":[136,218],"(Shaw;":[137],"i.p.)":[138],"animal":[139,158],"model":[140],"previously":[141],"reported":[142],"unresponsive":[144],"213Bi-Herceptin":[146],"0.002).":[149],"Multiple":[150],"dosing":[151],"evaluated":[155],"both":[157],"models.":[159],"median":[161,207],"3":[166,178],"110":[173],"days,":[174],"up":[176],"doses":[179,200],"given":[182],"at":[183],"approximately":[184],"monthly":[185],"intervals;":[186],"however,":[187],"there":[188],"no":[190],"evidence":[191],"correlation":[194],"second":[197],"third":[199],"0.98).":[203],"No":[204],"improvement":[205],"noted":[210],"similar":[213],"regimen":[214],"Shaw":[217],"model.":[219]},"counts_by_year":[{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":6}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}